Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: May 27, 2009
Last updated: June 16, 2011
Last verified: June 2011
This phase 1 study is an 8-day treatment period, randomized, controlled, double-blind, 3 parallel-groups, monocentric study. The primary objective is to evaluate the effect of naproxcinod on the renal function when co-administered with furosemide in comparison to naproxen and placebo.

Condition Intervention Phase
Renal Hemodynamics
Drug: naproxcinod
Drug: Naproxen
Drug: placebo
Drug: furosemide
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Phase 1, Single-Center, Randomized, Parallel-group, Placebo- and Naproxen- Controlled, Double-blind Study to Evaluate the Effect of Naproxcinod 750 mg Bid Administered for 8 Days on the Renal Hemodynamics, Natriuretic and Renin Responses to a Single Bolus IV Dose of Furosemide 40 mg in Male Healthy Normotensive Volunteers

Resource links provided by NLM:

Further study details as provided by NicOx:

Primary Outcome Measures:
  • To evaluate the effect of naproxcinod on the renal function when co-administered with furosemide in comparison to naproxen and placebo [ Time Frame: Day 8, between H3 and H9 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • to assess the effect of naproxcinod on blood pressure (BP) in comparison with naproxen and placebo over 1 week and when co-administered with furosemide + to assess the general safety and tolerability [ Time Frame: for over 1 week ] [ Designated as safety issue: Yes ]
  • To evaluate the effect of naproxcinod when administered alone on renal function, after a week of administration, in comparison with naproxen and placebo. [ Time Frame: Day 8 at H4 ] [ Designated as safety issue: Yes ]

Enrollment: 31
Study Start Date: January 2009
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: naproxen Drug: Naproxen
Naproxen 500 mg bid
Experimental: naproxcinod Drug: naproxcinod
naproxcinod 750 mg bid
Drug: furosemide
Placebo Comparator: placebo Drug: placebo


Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy, non smoker male subjects aged 18 and 35 years (inclusive), at the Screening visit.
  2. Body Mass Index (BMI) strictly between 18 and 30 kg/m² (inclusive) with body weight≥ 50 kg at the Screening visit.
  3. Normal physical examination at the Screening visit.
  4. Normal ECG (12-lead) at the Screening visit, as judged by the Investigator.
  5. At Screening and run-in period visits , Systolic Blood Pressure (SBP) between 100 and 139 mmHg (inclusive) and Diastolic Blood Pressure (DBP) between 50 and 89 mmHg (inclusive).
  6. At Screening and run-in period visits, HR between 45 and 90 bpm (inclusive).
  7. Subjects must be able to understand the written information sheet and informed consent and comply with all study requirements.
  8. Subjects must provide a written, dated and signed informed consent prior to any study procedure.

Exclusion Criteria:

  1. A history of hypersensitivity reactions (such as asthma, rhinitis, or urticaria) to aspirin, naproxen or any other NSAIDs; or hypersensitivity or contraindications to organic nitrate drugs or hypersensitivity to furosemide or to sinistrine or PAH.
  2. Family history of hypertension which may disqualify the subject, as judged by the investigator..
  3. History of any clinically relevant gastrointestinal (such as gastritis or gastric ulcer), respiratory, psychiatric, neurologic, kidney, liver, cardiac disease, bleeding disorder, other disease/condition or abnormal physical finding which may interfere with the study objectives. The investigator may disqualify any subject for a sound medical or psychiatric reason.
  4. History or presence of ASAT >40UI/L, ALAT >40UI/L, serum bilirubin 3 times above the Upper Limit of Normal range at the Screening visit.
  5. Creatinine clearance inferior/equal to 80 ml/min as calculated with the Cockcroft-Gault formula (Appendix 5 of the protocol) at the Screening visit.
  6. Plasmatic potassium <3.5 mmole/L at the Screening visit.
  7. Seropositivity for HBs, HBc, HIV 1 or HIV 2 at the Screening visit.
  8. Donations of blood, plasma or platelets within 3 months prior to the Screening visit or donation planned during the 3 months following Day 8.
  9. Any clinically significant abnormal laboratory values at the Screening visit.
  10. At the Screening visit, after 1 minute in a standing position, a drop of more than 20 mmHg in SBP or 10 mmHg in DBP or a clinical manifestation of postural hypotension.
  11. Chronic use of any drugs (prescription or OTC) within 4 weeks prior to Visit 2 (single use of medication such as paracetamol for headache will be tolerated at the lowest possible dose).
  12. Intake of any Nitric Oxide Synthase Inhibitor within 1 month before Screening visit.
  13. History of drug addiction or alcohol abuse as defined by DSM IVR, diagnostic criteria for drug and alcohol abuse or drug addiction.
  14. Positive drug screening (opiates, cannabinoids, cocaine, benzodiazepines, amphetamines, barbiturates) at the Screening visit.
  15. Current participation or participation within 60 days prior to the Screening visit, in another investigational study, including the present study or any previous enrolment in a naproxcinod study.
  16. In custody due to an administrative or a legal decision, or under tutelage, or being admitted to a sanitary or social institution.
  17. Any direct or indirect involvement with the study conduct or staff at site or any family link with study site staff.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: NicOx
ClinicalTrials.gov Identifier: NCT00909519     History of Changes
Other Study ID Numbers: HCT3012-X-113 
Study First Received: May 27, 2009
Last Updated: June 16, 2011
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Naproxen-n-butyl nitrate
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Gout Suppressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Nitric Oxide Donors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Sodium Potassium Chloride Symporter Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on May 02, 2016